Source: C-Rad AB
C-RAD signs a contract for its GEMini portal imaging detector
C-RAD announced today that it has signed an agreement with a Chinese company Beijing HGPT Technology & Trade Co., Ltd regarding the procurement and cooperation around the GEMini Portal imaging and dosimetry detector.
Following the agreement HGPT has the right to develop a portal imaging solution for the Chinese market. As part of the agreement both companies intend to launch a clinical cooperation with Fudan University Shanghai Cancer Center for the purpose of building up a local reference site and to support the clinical implementation of GEMini in China. The objective is to develop a solution can be sold to hospitals to upgrade their existing linear accelerators with a portal imaging solution, but also to OEM customers within China.
GEMini™ is an X-ray detector optimized for so called Portal Imaging and Portal Dosimetry applications. Whereas Portal Imaging is providing and solution to position the patient based on the inner patient anatomy prior to treatment, Portal Dosimetry allows to monitor the does delivered to the patient during treatment. The GEMini detector has been developed from the beginning to comply with these new requirements. The unique design of the GEMini detector makes it highly radiation-resistant while at the same time providing optimal dosimetry performance.
The order has a value of approx. 1,5 MSEK and is booked as order intake in the first quarter. The delivery shall take place during 2018. HGPT is also acting as a distributor for C-RAD’s advanced patient positioning laser as well as the cutting-edge surface tracking systems.
Mrs. Wenbing, President HGPT comments:
“I am very glad to cooperate with C-RAD in this new project. HGPT and C-RAD have a very long cooperation which started with the first product that C-RAD introduced to the market. I am very excited about this cooperation to develop a new solution for the Chinese customers, to bring more value to the Chinese Radiation Therapy field and the Chinese Patients. This is also another strong message to our customers, that HGPT is a leading company within advanced Radiation Therapy Solutions.“
“This project is a good opportunity for C-RAD to present the performance of the detector.” says Tim Thurn, CEO and President of C-RAD AB, “While I am excited about this order and the technical progress we made, I am convinced that the sales of our surface tracking products will drive the main growth for the company in the mid-term. The interest in the market for very accurate patient positioning and monitoring is constantly increasing due to the broad implementation of high-precision treatment techniques. C-RAD is in a very good position to serve the customers with a cutting-edge solution.”
About Beijing HGPT Technology & Trade Co., Ltd.:
HGPT was founded in 1998. Its headquarter office is located in Beijing and has established offices in Shanghai and Xi’an already. HGPT is a Professional Supplier for total solutions for the radiotherapy market, serving a constantly growing customer base with professional consultation, sales and services.
About C-RAD
C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit http://www.c-rad.com
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com
This information is information that C-RAD AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 08:55 CET on March 8, 2018.